ALIVUS.NS Earnings — Alivus Life Sciences Limited

NSE

Updated Oct 30, 2026

Price —

Market Cap $171.6B

P/E 25.7

52W Range — – —

When is ALIVUS.NS's next earnings date?

Alivus Life Sciences Limited (ALIVUS.NS) has not announced its next earnings date yet. Its most recent earnings report was on Friday, October 30, 2026.

How did ALIVUS.NS do in its last earnings report?

In its most recent report on Oct 30, 2026, Alivus Life Sciences Limited posted EPS of $0.13 versus the $12.50 estimate, a miss of 99.0%. Revenue was $66.9M against a $6.42B estimate.

How much does ALIVUS.NS stock move after earnings?

ALIVUS.NS beat EPS estimates in 1 of its last 2 reported quarters.

About Alivus Life Sciences Limited

Alivus Life Sciences Limited, a Mumbai, India-headquartered entity established in 2001, operates as a subsidiary of Nirma Limited. Having rebranded from Glenmark Life Sciences Limited in December 2024, the company specializes in the development, production, and global commercialization of active pharmaceutical ingredients (APIs). Its market footprint spans India, Japan, Europe, and both North and Latin America, supported by substantial export operations. Alivus Life Sciences provides an extensive catalog of APIs, including olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib. These ingredients are utilized across a diverse array of therapeutic areas, such as cardiovascular diseases, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppression, respiratory and ophthalmological conditions, urology, and anti-infectives. Additionally, the company extends its expertise by offering contract development and manufacturing services (CDMO) to numerous multinational corporations and specialty pharmaceutical enterprises.